The treatment, called EOS-448, is in a phase 1 study involving patients with advanced solid tumours. GlaxoSmithKline and iTeos plan to begin testing the treatment’s administration with dostarlimab, another cancer antibody, in 2022.
GlaxoSmithKline will pay iTeos $625 million upfront, as well as up to $1.45 billion in potential milestones payments.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
